Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
178
-
Total 13F shares, excl. options
-
16.8M
-
Shares change
-
+180K
-
Total reported value, excl. options
-
$1.19B
-
Value change
-
+$6.54M
-
Put/Call ratio
-
0.77
-
Number of buys
-
92
-
Number of sells
-
-88
-
Price
-
$70.83
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q4 2018
222 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q4 2018.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 178 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.8M shares
of 27.8M outstanding shares and own 60.44% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.57M shares), Vanguard Group Inc (1.53M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.07M shares), STATE STREET CORP (961K shares), FARALLON CAPITAL MANAGEMENT LLC (925K shares), RENAISSANCE TECHNOLOGIES LLC (797K shares), JANUS HENDERSON GROUP PLC (748K shares), FIRST MANHATTAN CO (680K shares), DIMENSIONAL FUND ADVISORS LP (624K shares), and Krensavage Asset Management, LLC (535K shares).
This table shows the top 178 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.